by Bruce Sylvester – The selective serotonin reuptake inhibitor (SSRI) citalopram appears to impede development of amyloid beta, a plaque-forming peptide in the brain believed to be involved… read more.
by Bruce Sylvester – The selective serotonin reuptake inhibitor (SSRI) citalopram appears to impede development of amyloid beta, a plaque-forming peptide in the brain believed to be involved… read more.
by Bruce Sylvester – Colon cancer patients diagnosed before age 50 have more advanced stages of colon cancer at diagnosis but have better survival at all stages of… read more.
by Bruce Sylvester – Researchers report that a pooled analysis of two major trials suggests that short- and long-term outcomes of neoadjuvant chemotherapy followed by chemoradiotherapy in high-risk… read more.
by Bruce Sylvester – Gender and tumor location predict efficacy in first-line treatment metastatic colorectal cancer, researchers reported a poster presentation at ASCO 2014.
by Bruce Sylvester – The presence of the single nucleotide polymorphism (SNP) rs895374, located in UbcH7, an E2 ligase conducting neddylation of HECT E3 ligases involved in EGFR… read more.
by Bruce Sylvester – Intermittent strategies for delivering systemic treatment in metastatic colorectal cancer show no clinically significant superiority in overall survival rates when compared to continuous delivery,… read more.
by Bruce Sylvester – In the FIRE 3 trial, clinicians favored the use of second-line antibodies in patients with KRAS wild-type metastatic colorectal cancer (mCRC) with shorter first-line progression free… read more.
by Bruce Sylvester – KRAS exon 2 mutations are independent predictors of time to recurrence or disease-free survival among patients with stage III distal colon cancer who are receiving… read more.
by Bruce Sylvester – Metastatic colorectal cancer patients who achieved early response to first-line chemotherapy also achieved significantly higher rates of prolonged survival, compared to patients who did… read more.
by Bruce Sylvester – Survival based on primary site of disease is not significantly different among metastatic colorectal cancer patients, Australian researchers reported in a poster presentation at… read more.
by Bruce Sylvester – Metformin therapy at 500 twice daily (BID) is not protective against heart failure in non-diabetic patients following a heart attack, researchers reported on March… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
